Rina-S led to a 50% response charge, together with two full responses, in closely pretreated superior endometrial most cancers: © inventory.adobe.com.
Therapy with Rina-S (rinatabart sesutecan) led to a 50% confirmed response charge, together with two full responses, in closely pretreated superior endometrial most cancers, in response to a information launch from Genmab.
“Superior stage and recurrent endometrial most cancers typically result in resistance to straightforward of care choices. When this happens, prognosis worsens and remedy choices change into more and more restricted, leaving sufferers and clinicians to navigate tough choices,” Dr. Ira Winer stated within the launch. “These part 1/2 outcomes reveal encouraging information with Rina-S on this affected person inhabitants and help its additional improvement as a possible remedy for sufferers with superior and recurrent endometrial most cancers.”
Winer is the examine investigator and a professor within the Division of Gynecologic Oncology and Part I Developmental Therapeutics on the Karmanos Most cancers Institute, Wayne State College, positioned in Detroit, Michigan.
Glossary:
Antibody-drug conjugate (ADC): a focused most cancers remedy that hyperlinks an antibody to a chemotherapy drug, delivering remedy on to most cancers cells.
Goal response charge (ORR): share of sufferers whose most cancers shrinks or disappears after remedy, confirmed by follow-up scans.
Full response (CR): disappearance of all indicators of most cancers in response to remedy.
Median follow-up: the center size of time sufferers has been noticed after beginning remedy.
Median period of response: the center size of time sufferers maintains most cancers management after first responding to remedy.
After a median follow-up of seven.7 months, remedy with Rina-S each three weeks led to a 50% confirmed goal response charge, together with two full responses, amongst closely pretreated sufferers with superior endometrial most cancers who had skilled illness development following platinum-based chemotherapy and an immune checkpoint inhibitor. Median period of response has not but been reached.
Sufferers obtained both 100 milligrams per sq. meter (mg/m2) (22 sufferers) or 120 mg/m2 (42 sufferers) of the agent. Amongst these given 100 mg/m2, the confirmed general response charge was 50%, together with two full responses. Within the 120 mg/m2 group, the confirmed response charge was 47.1%, additionally demonstrating anti-tumor exercise. Median period of response had not but been reached on the time of study, with a median follow-up of seven.7 months within the 100 mg/m2 group and 9.8 months within the 120 mg/m2 group. Median ages have been 67 and 69.5 years within the respective cohorts, and sufferers had obtained a median of three prior remedies.
Introduced on the 2025 ASCO Annual Assembly in Chicago, Illinois, these information got here from the endometrial most cancers monotherapy dose growth B2 cohort of the multi-part RAINFOL-01 trial, which is evaluating the protection and efficacy of Rina-S in stable tumors.
Rina-S was evaluated in 64 sufferers with superior or recurrent endometrial most cancers that had progressed following remedy with each anti-PD-(L)1 remedy and platinum-based chemotherapy.
Widespread treatment-related unwanted side effects of any grade included diarrhea, shortness of breath, urinary tract an infection, headache, constipation, decreased urge for food, vomiting, fatigue and nausea. Severe unwanted side effects (grade 3 [severe] or increased) occurred in 32% of sufferers handled with Rina-S 100 mg/m² and 50% of those that obtained 120 mg/m². Blood-related unwanted side effects have been manageable with out main dose reductions and led to few remedy discontinuations. No indicators of eye issues, nerve harm or interstitial lung illness — unwanted side effects typically linked to antibody-drug conjugates — have been noticed.
“Rina-S represents the sort of innovation that defines our focus at Genmab, which is to develop wholly owned, novel antibody-based medicines which have the potential to remodel the remedy of most cancers and handle an unmet want, together with for sufferers with superior endometrial most cancers,” Dr. Judith Klimovsky, govt vice chairman and chief improvement officer of Genmab, stated within the information launch. “The encouraging early alerts in endometrial most cancers underscore our deep dedication to creating a significant influence for ladies with gynecologic cancers, the place remedy advances have lengthy lagged behind the necessity.”
What’s Rina-S?
Rina-S is an investigational antibody-drug conjugate focusing on folate receptor α (FRα), which is a protein typically discovered on sure most cancers cells. The drug combines a monoclonal antibody, a protease-cleavable linker, and exatecan, a chemotherapy payload that inhibits topoisomerase I. Rina-S is being studied in a number of cancers with restricted remedy choices, together with ovarian and endometrial most cancers.
In January 2024, it obtained quick observe designation from the Meals and Drug Administration to be used in sufferers with FRα-expressing platinum-resistant ovarian most cancers. Late-stage improvement is underway, together with ongoing analysis within the RAINFOL-01 trial and a deliberate part 3 examine in endometrial most cancers. Rina-S continues to be investigational, and its security and efficacy haven’t been established.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
